MX348228B - Cristal de derivados de 6,7-insaturado-7-carbamoil morfinano y metodo para producir el mismo. - Google Patents

Cristal de derivados de 6,7-insaturado-7-carbamoil morfinano y metodo para producir el mismo.

Info

Publication number
MX348228B
MX348228B MX2015008305A MX2015008305A MX348228B MX 348228 B MX348228 B MX 348228B MX 2015008305 A MX2015008305 A MX 2015008305A MX 2015008305 A MX2015008305 A MX 2015008305A MX 348228 B MX348228 B MX 348228B
Authority
MX
Mexico
Prior art keywords
carbamoyl
unsaturated
crystalline
producing same
morphinane derivative
Prior art date
Application number
MX2015008305A
Other languages
English (en)
Inventor
Yoshinori Tamura
Kenji Morimoto
Masanao Inagaki
Nobuhiro Haga
Kouichi Noguchi
Sohei Omura
Shinichi Oda
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MX348228B publication Critical patent/MX348228B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/06—Halogens; Compounds thereof
    • B01J27/08—Halides
    • B01J27/10—Chlorides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Formas cristalinas estables de un compuesto representado por la fórmula (IA): (ver Fórmula) una sal de adición de ácido, y/o un solvato del sismo son proporcinados por la presente invención, dichas formas cristalinas son extremadamente útiles como materiales para preparación de medicamentos; procedimientos novedosos para la preparación de derivados de 6,7-insaturado-7carbamoil morfinano también se proporcionan por la presente invención.
MX2015008305A 2010-11-12 2011-11-11 Cristal de derivados de 6,7-insaturado-7-carbamoil morfinano y metodo para producir el mismo. MX348228B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010253688 2010-11-12
PCT/JP2011/076034 WO2012063933A1 (ja) 2010-11-12 2011-11-11 ６，７－不飽和－７－カルバモイルモルヒナン誘導体の結晶およびその製造方法

Publications (1)

Publication Number Publication Date
MX348228B true MX348228B (es) 2017-05-31

Family

ID=46051070

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013005241A MX338392B (es) 2010-11-12 2011-11-11 Cristal de derivado de 6,7-insaturado-7-carbamoil morfinano y metodo para producir el mismo.
MX2015008305A MX348228B (es) 2010-11-12 2011-11-11 Cristal de derivados de 6,7-insaturado-7-carbamoil morfinano y metodo para producir el mismo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013005241A MX338392B (es) 2010-11-12 2011-11-11 Cristal de derivado de 6,7-insaturado-7-carbamoil morfinano y metodo para producir el mismo.

Country Status (26)

Country Link
US (6) US9108975B2 (es)
EP (2) EP2639234B1 (es)
JP (2) JP5070364B2 (es)
KR (2) KR101500915B1 (es)
CN (2) CN105131003B (es)
AU (2) AU2011327113B9 (es)
BR (1) BR112013011593B1 (es)
CA (1) CA2814195C (es)
CY (1) CY1123670T1 (es)
DK (1) DK2639234T3 (es)
ES (1) ES2746207T3 (es)
HR (1) HRP20191597T1 (es)
HU (1) HUE044933T2 (es)
IL (2) IL225725A (es)
LT (1) LT2639234T (es)
MX (2) MX338392B (es)
PH (1) PH12015501226A1 (es)
PL (1) PL2639234T3 (es)
PT (1) PT2639234T (es)
RS (1) RS59256B1 (es)
RU (2) RU2607084C2 (es)
SI (1) SI2639234T1 (es)
TW (2) TWI545124B (es)
UA (1) UA115028C2 (es)
WO (1) WO2012063933A1 (es)
ZA (1) ZA201301726B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
RS59256B1 (sr) * 2010-11-12 2019-10-31 Shionogi & Co Kristalni derivat 6,7-nezasićenog-7-karbamoil morfinana, i postupak njegove proizvodnje
ES2903149T3 (es) 2012-05-14 2022-03-31 Shionogi & Co Preparación que contiene derivado de 7-carbamoilmorfinano 6,7-insaturado
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
JP6100917B2 (ja) 2012-12-14 2017-03-22 パーデュー、ファーマ、リミテッド、パートナーシップ ピリドンモルフィナン類似体およびオピオイド受容体に対する生物活性
JP6163210B2 (ja) 2012-12-14 2017-07-12 パーデュー、ファーマ、リミテッド、パートナーシップ 窒素含有モルフィナン誘導体およびその使用
US8946255B2 (en) 2012-12-28 2015-02-03 Purdue Pharma L.P. Substituted morphinans and the use thereof
WO2014102587A1 (en) 2012-12-28 2014-07-03 Purdue Pharma L.P. 7,8-cyclicmorphinan analogs
BR112015020667A2 (pt) * 2013-03-15 2017-07-18 Genzyme Corp método de preparar inibidores de glucosilceramida sintase
US9969746B2 (en) 2013-12-05 2018-05-15 The University Of Bath Opioid compounds and their uses
US9340542B2 (en) 2013-12-26 2016-05-17 Purdue Pharma L.P. Propellane-based compounds and the use thereof
EP3560487A4 (en) * 2016-12-26 2020-07-29 Shionogi & Co., Ltd. PRODUCTION METHOD FOR FORMULATION WITH IMPROVED UNIFORMITY OF CONTENT
KR102201609B1 (ko) * 2019-04-19 2021-01-12 연성정밀화학(주) 날데메딘의 제조방법
JPWO2021100728A1 (es) * 2019-11-20 2021-05-27
CA3166777A1 (en) 2020-02-03 2021-08-12 Nigel Patrick Somerville CRAWFORD Methods for treating neurological symptoms associated with lysosomal storage diseases
TW202220648A (zh) 2020-07-24 2022-06-01 美商健臻公司 包含芬谷司他(venglustat)之醫藥組合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2801509A1 (de) 1978-01-12 1979-07-19 Schering Ag 1,2,4-oxadiazolderivate, verfahren zur herstellung dieser verbindungen sowie diese enthaltende selektive herbizide mittel
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
WO2001002375A1 (en) * 1999-07-01 2001-01-11 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
DE10161963A1 (de) * 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
WO2006126529A1 (ja) * 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
RS59256B1 (sr) * 2010-11-12 2019-10-31 Shionogi & Co Kristalni derivat 6,7-nezasićenog-7-karbamoil morfinana, i postupak njegove proizvodnje

Also Published As

Publication number Publication date
IL225725A0 (en) 2013-06-27
US9296756B2 (en) 2016-03-29
AU2011327113B2 (en) 2015-06-25
TW201704239A (zh) 2017-02-01
EP3560929A3 (en) 2020-01-01
MX338392B (es) 2016-04-13
DK2639234T3 (da) 2019-09-23
ES2746207T3 (es) 2020-03-05
US9951082B2 (en) 2018-04-24
US9464094B2 (en) 2016-10-11
RU2607084C2 (ru) 2017-01-10
HRP20191597T1 (hr) 2019-11-29
BR112013011593B1 (pt) 2022-02-22
PH12015501226B1 (en) 2015-09-07
AU2015221439B2 (en) 2016-07-14
EP2639234B1 (en) 2019-07-03
JP2012162527A (ja) 2012-08-30
PL2639234T3 (pl) 2019-12-31
EP3560929A2 (en) 2019-10-30
LT2639234T (lt) 2019-09-25
MX2013005241A (es) 2013-05-28
RU2643807C1 (ru) 2018-02-06
SI2639234T1 (sl) 2019-10-30
HUE044933T2 (hu) 2019-11-28
IL225725A (en) 2017-09-28
US20160031896A1 (en) 2016-02-04
KR20140057410A (ko) 2014-05-12
BR112013011593A2 (pt) 2016-08-09
CN105131003A (zh) 2015-12-09
PH12015501226A1 (en) 2015-09-07
US20130231485A1 (en) 2013-09-05
US20180072748A1 (en) 2018-03-15
US9108975B2 (en) 2015-08-18
KR101500915B1 (ko) 2015-03-10
CA2814195C (en) 2020-03-10
TWI597282B (zh) 2017-09-01
US20160024102A1 (en) 2016-01-28
US20160194333A1 (en) 2016-07-07
UA115028C2 (uk) 2017-09-11
KR20130121119A (ko) 2013-11-05
WO2012063933A1 (ja) 2012-05-18
AU2011327113A8 (en) 2015-07-16
AU2011327113A1 (en) 2013-05-02
TWI545124B (zh) 2016-08-11
ZA201301726B (en) 2014-08-27
JPWO2012063933A1 (ja) 2014-05-12
RS59256B1 (sr) 2019-10-31
CN103298819B (zh) 2015-07-08
KR101486686B1 (ko) 2015-01-26
CA2814195A1 (en) 2012-05-18
RU2013126801A (ru) 2014-12-20
JP5070364B2 (ja) 2012-11-14
TW201300392A (zh) 2013-01-01
EP3560929B1 (en) 2021-05-19
EP2639234A4 (en) 2014-04-23
US20170066774A1 (en) 2017-03-09
JP5191574B2 (ja) 2013-05-08
CN105131003B (zh) 2017-09-26
AU2015221439A1 (en) 2015-09-17
US9315512B2 (en) 2016-04-19
AU2011327113B9 (en) 2015-07-30
US9902732B2 (en) 2018-02-27
EP2639234A1 (en) 2013-09-18
PT2639234T (pt) 2019-09-27
AU2011327113B8 (en) 2015-07-16
CY1123670T1 (el) 2021-10-29
IL243188A (en) 2017-12-31
CN103298819A (zh) 2013-09-11

Similar Documents

Publication Publication Date Title
MX348228B (es) Cristal de derivados de 6,7-insaturado-7-carbamoil morfinano y metodo para producir el mismo.
IN2014MN02106A (es)
WO2013091775A3 (de) Verwendung von cyclohexanolderivaten als antimikrobielle wirkstoffe
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
TN2013000253A1 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MX361618B (es) Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas.
UA105229C2 (uk) Фармацевтичний склад
NZ707389A (en) Process for preparing bile acid derivatives
NO20091858L (no) Hydrobenzamid derivater som inhibitorer av HSP90
MX2013000295A (es) Procedimiento de preparacion de un inhibidor especifico de la trombina.
MX340360B (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
MX2011011776A (es) Nuevos profarmacos de triptolite.
UA110128C2 (uk) Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
WO2011159124A3 (ko) Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
MX2010009876A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexanocarboxilico por medio del derivado de ciclohexanocarboxamida correspondiente.
MX2013000013A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparacion, y las composiciones farmaceuticas que la contienen.
EP4282973A3 (en) Processes for the preparation of pyrimidinylcyclopentane compounds
PH12017500435A1 (en) A salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
PH12015501056A1 (en) 2-pyridone compound
WO2013062332A3 (ko) 시링가레시놀을 포함하는 혈관 노화 억제용 조성물
WO2011161255A3 (en) Processes for the resolution of nitrogen substituted (s) - 5 -alkoxy- 2 -aminotetralin derivatives
TW201612188A (en) The L-proline complex, monohydrate and crystal of a sodium-glucose contransporter 2 inhibitor
MX2013005568A (es) Derivado de sulfuro de difenilo y producto farmaceutico que contiene el mismo como ingrediente activo.